Yiğit Özay Hülya, Yazıcıoğlu Alkın, Bindal Mustafa, Şahin Furkan, Yekeler Erdal, Turan Sema
Department of Anesthesiology and Reanimation, Ankara City Hospital, Ankara, Türkiye.
Department of Thoracic Surgery and Lung Transplant, Ankara City Hospital, Ankara, Türkiye.
Turk Gogus Kalp Damar Cerrahisi Derg. 2023 Jan 30;31(1):78-86. doi: 10.5606/tgkdc.dergisi.2023.22917. eCollection 2023 Jan.
This study aims to evaluate the effect of intraoperative fluid therapy on intensive care process and first 90-day morbidity and mortality in patients undergoing lung transplantation.
Between March 2013 and December 2020, a total of 77 patients (64 males, 13 females; mean age: 47.6±13.0 years; range, 19 to 67 years) who underwent lung transplantation were retrospectively analyzed. The patients were divided into two groups according to the amount of fluid given intraoperatively: Group 1 (<15 mL/kg/h) and Group 2 (>15 mL/kg/h). Demographic, clinical, intra- and postoperative data of the patients were recorded.
Less than 15 mL/kg-1/h-1 f luid w as a dministered t o 75.3% (n=58) of the patients (Group 1) and 24.7% (n=19) were administered more than 15 mL/kg-1/h-1 (Group 2). In t erms of native disease, the rate of diagnosis of chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis was higher in Group 1, and the rate of other diagnoses was higher in Group 2 (p<0.01). The ratio of women in Group 2 was higher (p<0.05), while the body mass index values were significantly lower in this group (p<0.01). The erythrocyte, fresh frozen plasma, platelet, crystalloid and total fluid given in Group 2 were significantly higher (p<0.001). Inotropic/vasopressor agent use rates and extracorporeal membrane oxygenation requirement were significantly higher in Group 2 (p<0.01). Primary graft dysfunction, gastrointestinal complications, and mortality rates were also significantly higher in Group 2 (p<0.05).
The increased intraoperative fluid volume in lung transplantation is associated with primary graft dysfunction, gastrointestinal complications, and mortality rates.
本研究旨在评估术中液体治疗对肺移植患者重症监护过程及术后90天内发病率和死亡率的影响。
回顾性分析2013年3月至2020年12月期间共77例行肺移植的患者(64例男性,13例女性;平均年龄:47.6±13.0岁;范围19至67岁)。根据术中给予的液体量将患者分为两组:第1组(<15 mL/kg/h)和第2组(>15 mL/kg/h)。记录患者的人口统计学、临床、术中和术后数据。
75.3%(n = 58)的患者(第1组)术中给予的液体量少于15 mL/kg-1/h-1,24.7%(n = 19)的患者给予的液体量超过15 mL/kg-1/h-1(第2组)。就原发病而言,第1组慢性阻塞性肺疾病和特发性肺纤维化的诊断率较高,第2组其他诊断的比例较高(p<0.01)。第2组女性比例较高(p<0.05),而该组的体重指数值显著较低(p<0.01)。第2组给予的红细胞、新鲜冰冻血浆、血小板、晶体液和总液体量显著更高(p<0.001)。第2组使用血管活性药物/血管加压药物的比例和体外膜肺氧合需求显著更高(p<0.01)。第2组原发性移植功能障碍、胃肠道并发症和死亡率也显著更高(p<0.05)。
肺移植术中液体量增加与原发性移植功能障碍、胃肠道并发症和死亡率相关。